바로가기  >

Abstract
Endothelial-to-mesenchymal transition (EndMT) involves the phenotypic conversion of endothelial-to-mesenchymal cells, and was first discovered in association with embryonic heart development. EndMT can regulate various processes, such as tissue fibrosis and cancer. Recent findings have shown that EndMT is related to resistance to cancer therapy, such as chemotherapy, antiangiogenic therapy, and radiation therapy. Based on the known effects of EndMT on the cardiac toxicity of anticancer therapy and tissue damage of radiation therapy, we propose that EndMT can be targeted as a strategy for overcoming tumor resistance while reducing complications, such as tissue damage. In this review, we discuss EndMT and its roles in damaging cardiac and lung tissues, as well as EndMT-related effects on tumor vasculature and resistance in anticancer therapy. Modulating EndMT in radioresistant tumors and radiation-induced tissue fibrosis can especially increase the efficacy of radiation therapy. In addition, we review the role of hypoxia and reactive oxygen species as the main stimulating factors of tissue damage due to vascular damage and EndMT. We consider drugs that may be clinically useful for regulating EndMT in various diseases. Finally, we argue the importance of EndMT as a therapeutic target in anticancer therapy for reducing tissue damage.

Affiliations

Kyu Jin Choi  1 , Jae-Kyung Nam  1 , Ji-Hee Kim  1 , Seo-Hyun Choi  2 , Yoon-Jin Lee  3
1 Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, 139-706, Korea.
2 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
3 Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, 139-706, Korea. yjlee8@kirams.re.kr.